Skip to main content
. 2003 Nov 15;112(10):1506–1520. doi: 10.1172/JCI19301

Figure 3.

Figure 3

Expression of activation antigens by B cells diminishes with different kinetics following treatment of active-SLE patients with humanized anti-CD154 (5c8). Freshly isolated PBMCs from normal volunteers and active-SLE patients before treatment, during treatment, and after treatment (SLE no. 1, 2 months after; SLE no. 2, 20 months after; SLE no. 3, 3 months after; SLE no. 4, 20 months after) were assessed for CD69 and CD38 expression in CD19+ B cell subsets by FACS analysis following staining with FITC-conjugated anti-IgD, APC-conjugated anti-CD19, and PE-conjugated Ab against CD69 or CD38. The percentages of CD19+ pre-switch IgD+ and post-switch IgD– B cells expressing CD38 (a) and CD69 (b) before, during, and after treatment are shown.